XML 24 R7.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Scioderm
Common Stock
Scioderm
Additional Paid-In Capital
Scioderm
Callidus
Common Stock
Callidus
Additional Paid-In Capital
MiaMed
Common Stock
MiaMed
Additional Paid-In Capital
MiaMed
Common Stock
Additional Paid-In Capital
Warrants
Accumulated Other Comprehensive Gain/ (Loss)
Accumulated Deficit
Total
Balance at Dec. 31, 2013                 $ 679 $ 423,593   $ 1 $ (378,522) $ 45,751
Balance (in shares) at Dec. 31, 2013                 61,975,416          
Increase (Decrease) in Stockholders' Equity                            
Stock issued from exercise of stock options, net                 $ 10 3,663       3,673
Stock issued from exercise of stock options, net (in shares)                 965,544          
Stock issued for acquisition       $ 24 $ (24)                  
Stock issued for acquisition (in shares)       2,359,593                    
Stock issued from public offering / financing                 $ 159 97,010       97,169
Stock issued from public offering / financing (in shares)                 15,927,500          
Stock issued from ATM transactions                 $ 143 38,493       38,636
Stock issued from ATM transactions (in shares)                 14,328,224          
Stock-based compensation                   6,008       6,008
Unrealized holding gain/(loss) on available-for-sale securities                       (133)   (133)
Net loss                         (68,926) (68,926)
Balance at Dec. 31, 2014                 $ 1,015 568,743   (132) (447,448) 122,178
Balance (in shares) at Dec. 31, 2014                 95,556,277          
Increase (Decrease) in Stockholders' Equity                            
Stock issued from exercise of stock options, net                 $ 21 11,165       11,186
Stock issued from exercise of stock options, net (in shares)                 2,070,300          
Stock issued for acquisition $ 59 $ 82,787 $ 82,846                      
Stock issued for acquisition (in shares) 5,921,771     25,762                    
Stock issued from public offering / financing                 $ 195 242,847       243,042
Stock issued from public offering / financing (in shares)                 19,528,302          
Stock issued from exercise of warrants                 $ 16 3,984       4,000
Stock issued from exercise of warrants (in shares)                 1,600,000          
Restricted stock vesting                   (2,044)       (2,044)
Restricted stock vesting (in shares)                 324,622          
Warrants issued in debt financing                     $ 8,755     8,755
Stock-based compensation                   9,972       9,972
Unrealized holding gain/(loss) on available-for-sale securities                       17   17
Net loss                         (132,118) (132,118)
Balance at Dec. 31, 2015                 $ 1,306 917,454 8,755 (115) (579,566) $ 347,834
Balance (in shares) at Dec. 31, 2015                 125,027,034         125,027,034
Increase (Decrease) in Stockholders' Equity                            
Stock issued from exercise of stock options, net                 $ 7 3,029       $ 3,036
Stock issued from exercise of stock options, net (in shares)                 723,102          
Stock issued for acquisition           $ 8 $ 4,599 $ 4,607            
Stock issued for acquisition (in shares)           825,603                
Stock issued from ATM transactions                 $ 150 96,918       97,068
Stock issued from ATM transactions (in shares)                 14,989,027          
Restricted stock vesting                   (1,282)       (1,282)
Restricted stock vesting (in shares)                 268,425          
Stock issued for contingent consideration                 $ 9 6,106       6,115
Stock issued for contingent consideration (in shares)                 858,795          
Receivable from investor                   932       932
Warrants issued in debt financing                     7,321     7,321
Equity component of the Convertible Notes issuance, net of issuance costs of $2,709                   88,346       88,346
Premium paid for Capped Call Confirmations                   (13,450)       (13,450)
Stock-based compensation                   17,504       17,504
Unrealized holding gain/(loss) on available-for-sale securities                       217   217
Foreign currency translation adjustment                       1,945   1,945
Net loss                         (200,042) (200,042)
Balance at Dec. 31, 2016                 $ 1,480 $ 1,120,156 $ 16,076 $ 2,047 $ (779,608) $ 360,151
Balance (in shares) at Dec. 31, 2016                 142,691,986         142,691,986